July 20, 2022
Daiichi Sankyo said on July 19 that its HER2 directed antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) being codeveloped with AstraZeneca obtained approval in Europe for the earliest lines of treatment for patients with HER2-positive breast cancer. The drug was...read more